FF/GW642444 Inhalation Powder

DRUG4 trials

Sponsors

GlaxoSmithKline

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 3

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01009463

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2009-09-25End: 2011-10-31Updated: 2017-11-09

A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01017952

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2009-09-25End: 2011-10-17Updated: 2018-08-31

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01053988

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2009-10-05End: 2011-04-14Updated: 2018-07-12

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01054885

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2009-10-19End: 2011-02-08Updated: 2018-01-24

Related Papers

A Combined Model‐Based Meta‐Analysis of Aggregated and Individual <scp>FEV1</scp> Data From Randomized <scp>COPD</scp> Trials

CPT Pharmacometrics & Systems Pharmacology2025-06-19

Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis.

2020-01-0620 citations

Predictors of pneumonia on routine chest radiographs in patients with COPD: a post hoc analysis of two 1-year randomized controlled trials.

2018-01-084 citations

Genetic evaluation of the effect of GLCCI1 rs37973 on corticosteroid response in chronic obstructive pulmonary disease

COPD Research and Practice2017-01-176 citations

LATE-BREAKING ABSTRACT: Blood eosinophils (EOS) are a biomarker of COPD exacerbation reduction with inhaled corticosteroids (ICS): An across-trials model-based approach

2016-09-015 citations

Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis

BMJ Open2016-06-0147 citations

Effect of fluticasone furoate (FF)/vilanterol (VI) compared with VI on acute exacerbations of COPD (AECOPD): A post-hoc analysis by baseline airflow obstruction

2015-09-01

Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD

Annals of the American Thoracic Society2014-12-09154 citations

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

2013-04-12243 citations

A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.

2013-01-2371 citations

Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.

2013-01-1687 citations